Physician profile
Peter V Sguigna
NPI 1033529789
$37,866.65
in general payments reported to CMS, 2019-2025
9 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $635 · 2021: $7,992 · 2022: $5,949 · 2023: $4,879 · 2024: $156 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $2,700 · Food and Beverage: $985 · Travel and Lodging: $870 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,175.00 |
| Honoraria | $2,700.00 |
| Food and Beverage | $984.51 |
| Travel and Lodging | $870.04 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $15,936.32 | 2020-2025 | |
| Genentech USA, INC. | $9,423.75 | 2021-2024 | Ocrevus |
| Amgen INC. | $6,017.06 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $3,126.18 | 2021-2023 | Uplizna |
| Ares Trading Sa | $1,800.00 | 2023 | Evobrutinib |
| Celgene Corporation | $1,500.00 | 2019 | |
| Genentech, INC. | $47.95 | 2020 | |
| Tg Therapeutics, INC. | $15.39 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sguigna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.